Artificial intelligence tools designed to screen for oral cancer may harbor a critical blind spot that could compromise diagnostic accuracy for millions of patients with darker skin tones, according to researchers from the Indian Council of Medical Research. The warning, published in npj Digital Medicine, highlights how AI systems like MeMoSA have been validated almost exclusively in Asian populations and may struggle to distinguish between normal pigmentation variation and pathological lesions in racially diverse settings.

The Pigmentation Problem in AI Diagnostics

The researchers identified two potential failure modes stemming from physiologic oral pigmentation, which varies naturally by race independent of any disease process. First, AI systems may generate false positives by flagging normal pigmentation variations as suspicious lesions, potentially subjecting patients to unnecessary biopsies and anxiety. Second, and perhaps more concerning, these tools may produce false negatives when actual pathological lesions are camouflaged by existing pigmentation, leading to missed cancer diagnoses.

Authors D. Khanna and A. Grover draw explicit parallels to well-documented failures in other medical AI applications. Pulse oximetry devices have been shown to perform less accurately in patients with darker skin, while dermatology AI systems have demonstrated reduced diagnostic performance across different skin tones. The researchers argue that oral cancer screening AI may be poised to replicate these equity failures unless developers take proactive steps to address pigmentation diversity.

Call for Pigmentation-Stratified Validation

Before deploying AI oral cancer screening tools in racially diverse populations such as the United States, the authors recommend conducting pigmentation-stratified validation studies. This approach would systematically test AI performance across different levels and patterns of oral pigmentation, ensuring that diagnostic accuracy remains consistent regardless of a patient's racial or ethnic background.

The recommendation carries significant implications for both healthcare providers and AI developers. Clinicians using these tools in diverse patient populations may unknowingly experience differential diagnostic accuracy based on patient race, potentially perpetuating existing health disparities in oral cancer detection and outcomes. For health technology companies, the call for race- and pigmentation-stratified validation adds development time and cost but may be essential for regulatory approval and clinical deployment in diverse markets.

Implications for Health Equity

The analysis underscores a broader challenge facing medical AI: ensuring that algorithmic tools trained primarily on homogeneous populations can perform equitably across the full spectrum of human diversity. Racial minorities with physiologic oral pigmentation may receive substandard screening accuracy if these validation gaps remain unaddressed, further widening health disparities in cancer care.

The research received no external funding, with both authors supported through salaried positions at the Indian Council of Medical Research. Their perspective adds to growing calls within the medical AI community for diverse training datasets and rigorous equity testing before clinical deployment of algorithmic diagnostic tools.

Sources

  1. Beyond skin deep: physiologic oral pigmentation as an overlooked validation gap in AI-assisted oral cancer screening — npj Digital Medicine